Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Net Income towards Common Stockholders (2023 - 2026)

Contineum Therapeutics' Net Income towards Common Stockholders history spans 4 years, with the latest figure at -$14.4 million for Q1 2026.

  • Quarterly Net Income towards Common Stockholders rose 9.95% to -$14.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$58.3 million through Mar 2026, down 17.07% year-over-year, with the annual reading at -$59.8 million for FY2025, 41.54% down from the prior year.
  • Net Income towards Common Stockholders came in at -$14.4 million for Q1 2026, up from -$15.1 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $41.6 million in Q2 2023 to a low of -$16.0 million in Q2 2025.
  • The 4-year median for Net Income towards Common Stockholders is -$10.3 million (2024), against an average of -$7.2 million.
  • Year-over-year, Net Income towards Common Stockholders plummeted 121.66% in 2024 and then rose 9.95% in 2026.
  • Contineum Therapeutics' Net Income towards Common Stockholders stood at -$7.8 million in 2023, then crashed by 87.48% to -$14.6 million in 2024, then decreased by 3.71% to -$15.1 million in 2025, then rose by 4.67% to -$14.4 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Net Income towards Common Stockholders are -$14.4 million (Q1 2026), -$15.1 million (Q4 2025), and -$12.8 million (Q3 2025).